Find Out The Best News, Guides and Info About Finance and Investments
- Latest News
Sun Pharma deal structurally strong, debt the only overhang: Amit Khurana
Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma’s acquisition is seen as strategically sound, though debt requires careful management.
“No Bull, no bear—it’s a kangaroo market,” says Nilesh Shah amid global uncertainty
Indian markets show a recovery but face a “kangaroo market” due to global risks like West Asian tensions and oil price volatility. Investors are urged
Rising input costs continue to pressure Reliance’s O2C business: Yogesh Patil
Reliance Industries navigates tough market conditions. Refining margins face volatility due to rising costs. Global crack spreads show improvement, but structural issues persist. The company’s
Range-bound trend likely as investors shift focus beyond heavyweights: Narendra Solanki
Indian markets are stabilizing as earnings season unfolds. Early IT sector results have lowered expectations. The market is now shifting focus to broader sectors and
Paytm shares crash 8% as RBI cancels Paytm Payments Bank’s banking licence. What next?
Paytm shares are set to remain in focus after the RBI cancelled Paytm Payments Bank’s licence, prompting its closure. The company expects no material impact
Sun Pharma shares jump over 4% after firm announces $12-billion Organon acquisition
Sun Pharmaceutical Industries’ shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in women’s health. This strategic move
Sun Pharma deal structurally strong, debt the only overhang: Amit Khurana
Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma’s acquisition is seen as strategically sound, though debt requires careful management.
“No Bull, no bear—it’s a kangaroo market,” says Nilesh Shah amid global uncertainty
Indian markets show a recovery but face a “kangaroo market” due to global risks like West Asian tensions and oil price volatility. Investors are urged
Rising input costs continue to pressure Reliance’s O2C business: Yogesh Patil
Reliance Industries navigates tough market conditions. Refining margins face volatility due to rising costs. Global crack spreads show improvement, but structural issues persist. The company’s
Range-bound trend likely as investors shift focus beyond heavyweights: Narendra Solanki
Indian markets are stabilizing as earnings season unfolds. Early IT sector results have lowered expectations. The market is now shifting focus to broader sectors and
Paytm shares crash 8% as RBI cancels Paytm Payments Bank’s banking licence. What next?
Paytm shares are set to remain in focus after the RBI cancelled Paytm Payments Bank’s licence, prompting its closure. The company expects no material impact
Sun Pharma shares jump over 4% after firm announces $12-billion Organon acquisition
Sun Pharmaceutical Industries’ shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in women’s health. This strategic move